Safety, Tolerability and Pharmacokinetics of Single Doses of the Trpv1 Antagonist SAF 312 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2014
At a glance
- Drugs SAF 312 (Primary)
- Indications Dental pain; Neurogenic bladder; Postoperative pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Institutes for BioMedical Research
- 14 Apr 2014 New trial record
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.